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Abstract
In confirmatory cancer clinical trials, overall survival (OS) is normally a primary endpoint in
the intention-to-treat (ITT) analysis under regulatory standards. After the tumor progresses,
it is common that patients allocated to the control group switch to the experimental treatment,
or another drug in the same class. Such treatment switching may dilute the relative efficacy
of the new drug compared to the control group, leading to lower statistical power. It would
be possible to decrease the estimation bias by shortening the follow-up period but this may
lead to a loss of information and power. Instead we propose a modified weighted log-rank test
(mWLR) that aims at balancing these factors by down-weighting events occurring when many
patients have switched treatment.
As the weighting should be pre-specified and the impact of treatment switching is unknown,
we predict the hazard ratio function and use it to compute the weights of the mWLR. The
method may incorporate information from previous trials regarding the potential hazard ratio
function over time.
We are motivated by the RECORD-1 trial of everolimus against placebo in patients with
metastatic renal-cell carcinoma where almost 80% of the patients in the placebo group received
everolimus after disease progression. Extensive simulations show that the new test gives con-
siderably higher efficiency than the standard log-rank test in realistic scenarios.
Keywords: confirmatory trials; non-proportional hazards; treatment switching; weighted
log-rank test.
1 Introduction
Research in oncology has been increasing over the past years. This can be seen for example by an
increased proportion of cancer trials registered at clinicaltrials.gov. In years 2007-2010, trials
in oncology comprised 21.6% [18] while in 2017 the number rose to almost 35% of all registered
trials [44]. In December 2018 the Food and Drug Administration (FDA) in the US updated their
guidance “Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics” [16] with
recommendations on the choice of appropriate endpoints when performing clinical trials in oncology.
Overall survival (OS) is considered by regulatory authorities as the most relevant and reliable clinical
endpoint. However, it usually requires a long follow-up which could delay approval of a beneficial
treatment. It is therefore common to use a surrogate endpoint that is a good predictor of OS.
One endpoint that is frequently used in trials and allows for accelerated approval is progression-free
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survival (PFS). In some situations, PFS might be enough to obtain traditional regulatory approval
[33, 11, 19, 22]. Carneiro et al. [9] published an overview of accelerated and traditional regulatory
approvals in oncology. However, in most cases, the traditional approval can only be obtained after
showing efficacy also on OS and the accelerated approval might be withdrawn if the due diligence
is not demonstrated [16].
For ethical reasons, a patient may switch treatment after disease progression. Such switching
will not have an impact on PFS, but it may have a high impact on OS. Patient crossover might
result in a diluted effect on OS, decreasing the power of the study. See for example the RECORD-1
trial [12] presented in Section 2. Even in the presence of patient crossover, it is preferred by the
regulatory authorities to perform an intention-to-treat (ITT) analysis [27] where treatment groups
are compared as originally randomized. Using ITT as the primary analysis has been criticized as
it tends to underestimate the true treatment effect [27]. On the other hand, ITT analysis is robust
in the sense that it is unlikely that any bias would inflate the type-I error rate.
It may be a clinically relevant question to estimate the efficacy that would have been observed if
no patients had switched in the study. Alternative approaches have been proposed in the literature
to address the issues of estimating the hazard ratio in the presence of treatment switching. These
methods focus on the issues of estimation and bias mainly in the context of Health Technology
Assessments (HTAs). They include the use of a per protocol analysis that either censors patients
at the time of switching, or removes them from the analysis set [25, 27, 13], which can result in a
selection bias. More complex methods include inverse probability of censoring weighting (IPCW)
[40], rank-preserving structural failure time (RPSFT) model [38] and two-stage adjustments [39, 45]
that were further simplified [24, 26]. Advantages and disadvantages of all methods have been
discussed by researchers and regulatory authorities [13, 25, 17, 32, 27]. These methods have proven
to have a smaller bias than simply using the ITT method under some circumstances [24]. Latimer
et al. [26] showed that RPSFT model, IPCW and two-stage adjustment are likely to provide
good approximations of the true treatment effect as long as the proportion of patients switching
treatments is moderate. However, EMA [13] points out that “RPSFT models will typically not
change the p-value, and while IPCW and ’two-stage’ methods might, confidence intervals for all
three methods tend to be wide”, meaning that while estimates of hazard ratio might be less biased,
the power of the trial will not be increased. Furthermore, it is stressed that underlying assumptions
of these methods cannot be proven to be true [13]. As noted above, it is still generally required to
base the primary analysis on the ITT set of patients and use the alternative methods as complements
to ITT [24, 26, 13]. EMA [13] stresses that “due to the uncertainties involved in the methods (...),
such estimations should, at present, be used primarily as supportive or sensitivity analyses”.
Lately, non-proportional hazards have been receiving a lot of attention since immuno-oncology
agents present what is known as a delayed treatment effect, which violates the proportional hazard
assumption [1]. In this case, a common model assumes lack of treatment differences at the beginning
of the trial (i.e., the hazard ratio is equal to 1) and treatment differences after some unknown time
point (i.e., the hazard ratio is no longer equal to 1). Alternatively, and perhaps more realistically,
one may assume that the relative treatment efficacy is gradually increasing over time. Methods
addressing the problem of power loss in that context include the restricted mean survival time
(RMST) [42], landmark analysis [10], accelerated failure time model [3], weighted Kaplan-Meier
statistics [34], weighted log-rank tests (e.g. with Fleming and Harrington class of weights [14]), Max
Combo test (taking the maximum value of a set of different weighted log rank tests) [28] and the
“modestly weighted log-rank test” [30]. Another approach could be to simply increase the sample
size in the trial accounting for the delayed effect, but this will be inefficient and in many situations
infeasible, considerably increasing the cost and length of the study.
It is well know that under proportional hazards, the log-rank test (LR) is optimal among all tests
based on the order of events (and censoring) [35, 43]. In the presence of delayed efficacy, though,
the weighted log-rank test shows superiority over the LR test in situations where the experimental
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arm is in fact better than the control. The test assigns a small weight at an early time in the study,
where no differences are expected, and a larger weight for later time points, where survival curves
are expected to separate. However, it was shown by Magirr and Burman [30] that the weighted log-
rank test (WLR) does not control the type-I error rate under some scenarios when the experimental
arm performs worse than the control. Treatment switching induces non-proportional hazards, where
the hazard ratio increases towards the end of the trial and dilutes power. Hence, a WLR test with
decreasing weights can then be used to increase power [5].
In this manuscript we propose a modified weighted log-rank (mWLR) test where the down-
weighting depends on how much treatment switching is expected in a setting where patients from
the control arm are allowed to switch treatment after disease progression. The article is divided into
the following sections. In Section 2 we introduce a motivating example based on the RECORD-1
trial. Section 3 presents the proposed mWLR test. In Section 4 we present the simulation set-up
we use to test the proposed mWLR test. In Section 5, we provide the results of the simulations
where the mWLR test is compared with LR and other alternative tests. In Section 6 we discuss
the main conclusions, the weaknesses and strengths of our proposal as well as further research.
2 Motivating example: The RECORD-1 trial
In this section we introduce a case study. It will be used as a realistic scenario in which we can
test the performance of our proposal and compare it with other methods. It is, however, not within
the scope of this article to re-analyze or make new clinical interpretations of the data. RECORD-1
was a phase III trial that examined the impact of everolimus (Afinitor; Novartis Pharmaceuticals
Corporation, East Hanover, NJ) on the primary endpoint of PFS, and the secondary endpoints
of OS and safety in metastatic renal-cell carcinoma (mRCC) patients, after treatment failure on
sunitinib or sorafenib. It was a double-blind, multicenter study with patients randomized to receive
either everolimus (n = 277) or placebo (n = 139) in a 2:1 ratio. Further details of the study design
as well as main results have been presented in Escudier et al. [12] and Korhonen et al. [23].
One important aspect of the trial is that placebo patients had the opportunity to receive
everolimus after disease progression, since existing literature already supported the antitumor ac-
tivity of everolimus and another mTOR inhibitor temsirolimus in this indication [2, 4]. The study
design therefore allowed for crossover to open-label everolimus following progression for patients
randomized to placebo. In fact, 106/139 placebo patients did switch to open-label everolimus after
disease progression. Furthermore, when the study was unblinded on February 28, 2008, a planned
interim analysis showed significant superiority of everolimus over placebo on the primary endpoint
PFS (hazard ratio (HR) 0.33; 95% confidence interval (CI) 0.25-0.43; LR test p-value < 0.001).
After this time, five of the remaining six patients still receiving placebo switched to open-label
everolimus, yielding a total of 111/139 placebo patients that switched to everolimus. Patients were
further followed up for survival until November 15, 2008. The ITT analysis of OS at this cut-off
date yielded a HR of 0.87, which was in favor of everolimus, although it was not statistically signif-
icant (95% CI 0.65-1.15; one-sided p-value = 0.162). What makes this case study interesting in our
context is that the OS results may have been biased due to the large extent of treatment switching.
In Figure 1A, we present the OS curves from the ITT analysis, in Figure 1B the OS curves
with only switchers in the placebo arm, and in Figure 1C the OS curves with only non-switchers in
the placebo arm. Without assumptions, the median OS for the placebo group cannot be directly
estimated from the plots although they provide an insight of what impact the treatment switching
could have had on OS in this trial. The median was in fact estimated using the rank-preserving
structural failure time (RPSFT) model [23] and the crossover-adjusted median OS estimate was
then close to 10 months.
3
Figure 1: Kaplan-Meier curves from the ITT analysis including all patients (plot A), with only
treatment switchers in the placebo arm (plot B), and with only non-switchers in the placebo arm
(plot C).
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3 Methods
3.1 The log-rank (LR) test
Let S(t) be the probability of survival at time t ≥ 0 and be defined by S(t) = 1 − F (t), where
F (t) is a differentiable cumulative distribution function. Let f(t) be the corresponding probability
density function. The hazard function can then be defined as h(t) = f(t)/S(t) = −S ′(t)/S(t).
Assume now that we have a clinical trial with a control arm and an experimental arm. The
corresponding survival and hazard functions are S0(t) and S1(t), and h0(t) and h1(t), respectively.
We test the following hypothesis:
H0 : S0(t) = S1(t) ∀ t vs. H1 : S0(t) < S1(t) ∃ t, (1)
to see if we have an effect on the experimental treatment arm. In clinical trials it is common practice
to use the hazard ratio (i.e., the ratio between the hazard functions of each treatment) to quantify
treatment differences. The hazard ratio function is defined as η(t) = h1(t)/h0(t).
To test this hypothesis we may use the LR test. Let t1 < · · · < tk be the k distinct, ordered
event times. The number of patients at risk at time tj is denoted by ni,j with nj := n0,j + n1,j. Let
di,j denote the number of events on arm i at time tj with dj := d0,j + d1,j. The LR test statistic is
then defined as
ULR =
k∑
j=1
(
d0,j − dj n0,j
nj
)
, (2)
where the expression inside the sum describes the difference in actual and under H0 expected
number of events on the control arm at each distinct time. Under the null hypothesis, we would
have E[ULR] = 0. The variance of ULR is given by Brown [6] as
V (ULR) =
k∑
j=1
(
n0,jn1,jdj(nj − dj)
n2j(nj − 1)
)
. (3)
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Figure 2: Power with the log-rank (LR) for different total number of events under two different
models: the proportional hazards model and the exponential progression switching model presented
in Section 3.3 where patients switch treatment after disease progression with probability p.
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For large sample sizes the test statistic ZLR = ULR/
√
V (ULR) is normally distributed with mean
0 and variance 1 under the null hypothesis, by the central limit theorem. For a model with propor-
tional hazards, meaning η(t) = c, where c > 0 is any constant, this unweighted LR test is optimal
(see Schoenfeld [43]) and power will increase with sample size. However, this is not the case under
the presence of treatment switching.
In Figure 2 we present a simple example that shows how the power behaves depending on the
number of events both under the proportional hazards model and under the presence of treatment
switching. More information about how the model is set up will be described in Section 3.3. Under
proportional hazards we see that, using the LR test, the power increases with the number of events.
However under treatment switching, using the LR test, we see that the power increases up to a
point, and then decreases.
3.2 Weighted log-rank (WLR) tests
Under the presence of treatment switching and following non-proportional hazards, the standard
LR test is suboptimal. An alternative is the WLR test, defined as
UWLR =
k∑
j=1
wj
(
d0,j − dj n0,j
nj
)
, (4)
with variance
V (UWLR) =
k∑
j=1
w2j
(
n0,jn1,jdj(nj − dj)
n2j(nj − 1)
)
. (5)
The test statistic is defined as ZWLR = UWLR/
√
V (UWLR) ∼ N(0, 1) under the null hypothesis
[14]. By setting the weights wj = 1 (or any constant) we will get the standard (and unweighted)
LR test.
Under the presence of treatment switching one expects a higher treatment effect in the beginning
of the study that will decrease as the study progresses. Intuitively, by down-weighting late events,
where treatment switching is expected to be high, we would achieve higher power than the standard
5
LR test. For instance, the well known Fleming and Harrington class of weights [14] have been
receiving a lot of attention over the last years, in particular with the development of immuno-
therapy (see e.g., Jime´nez et al. [20]), since they allow to down-weight early or late event using the
estimated pooled survival function Sˆ(t).
3.3 A modified weighted log-rank (mWLR) test based on exponential
progression switching
In this section, we develop a mWLR test that is tailored to a situation with considerable treatment
switching. Under the assumption that we know the true hazard rate function, the optimal LR
weights would be
wj = − log(ηj), (6)
where ηj represents the hazard ratio at time tj.
In a regulatory setting the hypothesis test has to be pre-specified, therefore we propose to derive
a hazard ratio model based on relevant clinical parameters and, through equation (6), obtain a
pre-specified weight function.
For simplicity, we assume exponential distributions for both progression and death. Let OS for
patients receiving the control and experimental treatment be defined respectively as
SOS0 (t) = exp
(−λOS0 · t) ,
SOS1 (t) = exp
(−λOS1 · t) . (7)
A PFS event is defined as either a disease progression or a death. We use independent exponential
distributions for these two components of the PFS event and define time to PFS as the minimum
of time to progression or death. Our model does not depend on progression in the experimental
group, as it is not affected by treatment switching, but we assume that time to progression in the
control group has survival functions
SP0 (t) = exp
(−λP0 · t) . (8)
As the competing progression and death risks are assumed to be independent and constant, the
probability r that a patient in the control group has a progression before dying is
r =
λP0
λP0 + λ
OS
0
. (9)
The total PFS hazard is the sum of the component hazards, hence
λPFS0 = λ
P
0 + λ
OS
0 . (10)
For the RECORD-1 trial, as for most other oncology phase III trials, the medians mPFSi and
mOSi for PFS and OS respectively, are provided in the main publication [12]. We have that
λOS0 = log(2)/m
OS
0 , (11)
and
λP0 = λ
PFS
0 − λOS0 = log(2)/mPFS0 − log(2)/mOS0 . (12)
Therefore if λP0 = log(2)/m
P
0 , it follows that
mP0 =
mPFS0 ·mOS0
mOS0 −mPFS0
. (13)
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Directly following a progression, patients in the control group are assumed to switch to exper-
imental treatment with probability p. Thus, the total probability that a control arm patients will
switch treatment before dying is defined as
q = P (progression)×P (patient switches treatment | progression) = r×p =
(
1− m
PFS
0
mOS0
)
×p. (14)
Note that this is the probability of the patient progressing and switching at some time point.
Progressions occurring after censoring will not be observed in a trial. Thus, the proportion of
patients switching treatment before a trial ends will often be somewhat less than q.
Given the characteristics of the RECORD-1 trial discussed in Section 2, a patient switching
from control to experimental treatment is assumed to switch OS hazard from λOS0 to λ
OS
1 . This
completes the model assumptions and we can now derive the hazard ratio function to obtain the
proposed weights. The rationale of the model assumptions as well as alternative model choices are
discussed in Section 6.
Patients randomized to the control group will belong, at a certain time t, to one of the following
4 categories: (i) non-progressed (np), (ii) progressed and having switched to experimental treatment
(ps), (iii) progressed non-switched (pns), or (iv) deceased. The flow between the Markov states is
shown in Figure 3 and the probabilities for the first 3 categories are given by the starting conditions
Snp(t) = 1, Sps(t) = 0 and Spns(t) = 0, as well as by the following differential equations:
dSnp(t)
dt
= −(λP0 + λOS0 ) · Snp(t),
dSps(t)
dt
= p · λP0 · Snp(t)− λOS1 · Sps(t),
dSpns(t)
dt
= (1− p) · λP0 · Snp(t)− λOS0 · Spns(t).
(15)
The solution to this system of differential equations is given by
Snp(t) = exp
(−(λP0 + λOS0 ) · t) ,
Sps(t) =
p · λP0
λP0 + λ
OS
0 − λOS1
· (exp (−λOS1 · t)− exp (−(λP0 + λOS0 ) · t)) ,
Spns(t) = (1− p) · (exp (−λOS0 · t)− exp (−(λP0 + λOS0 ) · t)) ,
(16)
and the total survival function for the control arm is therefore defined as
S0(t) = S
np(t) + Sps(t) + Spns(t) =
= (1−p) · exp(−λOS0 ·t) + p ·
λP0 · exp(−λOS1 ·t) + (λOS0 −λOS1 ) · exp
(−(λP0 +λOS0 ) · t)
λP0 + λ
OS
0 − λOS1
.
(17)
An obvious question is how this flow between Markov states translates into survival functions.
In Figure 4A we provide an example of the composition of patients over time for each survival group
as defined in equation (16). In Figure 4B we show the resulting survival function for the control
group (in teal). Moreover, in Figure 4B we also show the survival function for the experimental
arm (in brown) as well as the survival function for the control group under proportional hazards
(in pink) to make a visual comparison with the derived survival function for the control arm.
By definition, the hazard function for the control arm is h0(t) = −S ′0(t)/S0(t). As the PFS rate
is the sum of the progression and OS rates, λPFS0 = λ
P
0 + λ
OS
0 , it follows from equation (17) that
h0(t) =
v0(t) · λOS0 + v1(t) · λOS1 + v0p(t) · λPFS0
v0(t) + v1(t) + v0p(t)
, (18)
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Figure 3: Markov chain states and transition rates.
Non−progressed Deceased
Progressed
and
switched
Progressed
and
non−switched
λ0
OS
λ0
OS
λ1
OS
(1−p) . λ0P
p . λ0
P
where
v0(t) = (1− p) · (λPFS0 − λOS1 ) · exp(−λOS0 · t)
v1(t) = p · λP0 · exp(−λOS1 · t)
v0p(t) = p · (λOS0 − λOS1 ) · exp(−λPFS0 · t).
(19)
The hazard for the experimental arm simplifies to h1(t) = λ
OS
1 and we can calculate the hazard
ratio over time, η(t) = λOS1 /h0(t). Therefore, the weights defined in equation (6) are computed as
wj = −log(λOS1 /h0(tj)).
These weights will primarily depend on the assumed (conditional) treatment switching proba-
bility, p. Note that when p = 0 the model simplifies into a proportional hazards model that assigns
constant weights. That is, the proposed mWLR test coincides with the standard unweighted LR
test. A common time scale parameter will not alter the weights, in the sense that if all times and
time parameters are multiplied by a constant k, all weights remain the same. The assumed relation
between the median survival of experimental and control will have little impact on the test weights
except for the obvious change in power and for the fact that the initial value of wj is proportional
to the ratio between these medians of overall survivals. The test will have some dependency on the
relative medians for progression and overall survival, as the test differentiates between time points
with different proportions of non-deceased patients that have switched treatment.
In Figure 5A, we present the hazard ratio functions produced by the proposed model assuming
different values of p together with the real RECORD-1 hazard ratio. In Figure 5B, we present the
weight values obtained from equation (6) for each of the hazard ratio functions presented in Figure
5A.
In this section we have proposed a model that uses clinically relevant parameters to build a
realistic hazard ratio function that explains the impact of treatment switching in a clinical trial.
In fact, in Figure 5A we see that when using p = 1 the proposed hazard ratio function closely
approximates the hazard ratio function of the RECORD-1 trial. However, the true hazard ratio
function is unknown when designing a trial, and the best we can do is build a “guess” based on
prior clinical information from clinical trials with similar characteristics. In Sections 4 and 5 we
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Figure 4: Plot A shows the survival probability for non-progressed patients (red), progressed and
non-switched patients (green) and progressed and switched patients (blue) assuming p = 0.5,
mPFS0 = 2, m
OS
0 = 10, m
OS
1 = 15. In plot B, we show the resulting survival functions for the
control (teal) and experimental (brown) arms, and also as a comparison, the control arm under
proportional hazards (pink).
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implement an evaluation of the methodology presented in this section. To do so, we assume a true
hazard ratio function and a pre-specified hazard ratio function that will be our “best guess”. Let p
refer to the probability of treatment switching after disease progression from the true hazard ratio
function and p′ refer to the probability of treatment switching after disease progression from the
assumed (or “guessed”) hazard ratio function.
4 Simulation study set-up
In this section we conduct a comprehensive simulation study to investigate the operating character-
istics of the mWLR test with the hazard ratio model based on exponential progressions introduced
in Section 3.3. The entire simulation study is based on a single scenario set-up where sample size,
median OS, median PFS and total number of deaths are the same from those observed in the
RECORD-1 trial. These values are presented in Table 1.
Table 1: Median OS, median PFS, sample size, and total number number of deaths based on the
RECORD-1 trial.
Control Arm Experimental Arm
Median OS (months) 5-10 15
Median PFS (months) 2 4
Sample Size 139 277
Total number of deaths 221
Note that, in Table 1, the median OS in the control group ranges from 5 to 10 months as it is
not possible to obtain its real value from the RECORD-1 trial data given the impact of treatment
switching. The recruitment data was not taken from the RECORD-1 trial data and patients are
assumed to be enrolled uniformly during 12 months.
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Figure 5: Hazard ratio from the RECORD-1 trial and hazard ratio functions obtained with the
model based on exponential progression switching (plot A), and corresponding weights functions
from equation (6) (plot B), for p = (0, 0.2, 0.4, 0.6, 0.8, 1), mOS0 = 10 with m
OS
1 = 15 and m
PFS
0 = 2.
The weights using p = 0 are equivalent to those from the standard log-rank (LR) test.
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One may think of this set-up as if we would be designing a clinical trial similar to RECORD-1
trial, after having observed the RECORD-1 trial results. In other words, we are designing a clinical
with solid and reliable historical information that allows us to pre-specify a sensible hazard ratio
function. The performance of the mWLR test is compared with the performance of the standard
LR test in terms of power and efficiency. The empirical power for both tests is calculated as
PowerLR =
1
M
M∑
i=1
1
(
ZLRi > Φ
−1(1− α)) ,
PowermWLR =
1
M
M∑
i=1
1
(
ZmWLRi > Φ
−1(1− α)) , (20)
and the relative efficiency between mWLR and LR as
Efficiency =
(
ZmWLR
ZLR
)2
, (21)
where α = 0.025 and M = 104 corresponds to the number of simulations implemented implemented
in R [36] for each scenario. Equation (21) should be interpreted as the efficiency of mWLR with
respect to LR where values above 100% imply a better performance of the mWLR test with respect
to LR, and values below 100% imply a better performance of LR with respect to the mWLR test.
Let pˆi denote the estimated power. As M = 104 simulation runs are performed for each point in
power diagrams, the simulation error (95% confidence interval) is ±1.96 ·√pˆi(1− pˆi)/M , at most
±1.0 percentage points.
One of the key characteristics of this methodology is that it relies on the pre-specification of a
hazard ratio function that depends on prior values of median OS, median PFS and probability of
switching. As presented in Figure 5, depending on p, the hazard ratio function has different shapes.
However, if p′ is not close to p, the model may not work very well since the hazard ratio function
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would be misspecified. In the simulation study we primarily focus on evaluating the performance of
the proposed model under the presence of a high proportion of treatment switching. However, we
also make an evaluation in cases where p and p′ are not close, and compare the results with those
from the standard LR test.
Moreover, in order to provide an entire overview of the model performance we also compare
the mWLR test, in a scenario with a high values of p, with the test based on the restricted mean
survival time and the Max Combo test, which are known to have higher power than the standard
LR test under non-proportional hazards.
Note that we do not test on the real RECORD-1 data the proposed weight function built with
the model presented in Section 3.3 since it is out of the scope of this article re-analyzing or making
new clinical interpretations of the RECORD-1 trial data.
5 Results
5.1 Performance of the new test
In this section we present the results from the simulation set-up described in Section 4 that provides
a scenario that can be considered similar to the RECORD-1 trial and hence realistic.
We start this performance evaluation by considering the extreme case where all patients in the
control group switch treatment after disease progression (p = 1). If we take p′ = 1, this is the
scenario where mWLR has the greatest benefit compared to the standard LR test. Moreover, this
scenario would not be so far from what was observed in the RECORD-1 trial, where 111 out of the
139 patients randomized to the control arm switched treatment, giving an estimate for q of 80%.
We don’t know how many patients, in the control arm, died before progression but with reasonable
assumptions regarding the competing risks for progression and death (see equation (14)), p can be
expected to be considerably higher than q, although not exactly 1. Later on, we assess the test
performance for p′ = p ranging from 0 to 1.
In Section 5.2 we assess the robustness of the proposed test when the degree of treatment
switching is misspecified, with the test parameter p′ being different from p. Although the LR test
is currently the dominating analysis method, we compare mWLR also against other alternatives,
the Max Combo test and Restricted Mean Survival, in Section 5.3.
Throughout this section, we assume that median time to progression is mP0 = 2 months in the
control group. For the median OS, we assume mOS1 = 15 months for the experimental treatment,
while we consider a range of values for patients on control treatment. With no treatment switching
(p = 0) the unaffected hazard ratio for OS in our model would be HRu = m
OS
0 /m
OS
1 . Taking median
survival on control ranging from mOS0 = 5 months to m
OS
0 = 10 months, the unaffected HR ranges
from HRu = 5/15 ≈ 0.33 to HRu = 10/15 ≈ 0.67.
Figure 6 shows that mWLR is much more powerful and therefore efficient than the LR test
when p = p′ = 1 for different values of mOS0 . Obviously, the absolute increase in power depends on
how large the power is for the LR test. For example, when mOS0 = 5 and HRu ≈ 0.33, LR power is
equal to 96%, leaving limited room for further power increase. However, mWLR reaches a power of
99%. When HRu = 0.5, the absolute increase in power is larger, going from 45% up to 66%. The
efficiency with respect to LR goes from 143% to 171%. That is, the trial would have required a
much lower sample size if the proposed mWLR test would have been used instead of the standard
LR test.
In practice, HRu is unknown when planning the trial, so it is reasonable to consider the perfor-
mance of the tests over a range of HRu values. If results on PFS are very convincing and treatment
switching is high, it is not certain that regulators would require a formal statistical significance for
OS. It is therefore of importance that the increase in efficiency with mWLR would also lead to
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Figure 6: Power of the modified weighted log-rank (mWLR) test and the log-rank (LR) test (plot
A) and efficiency of the mWLR test with respect to the LR test (plot B) assuming p = 1 and p′ = 1
for values of mOS0 that range from 5 to 10 months and the corresponding hazard ratio η.
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lower p-values even if neither test reaches statistical significance. For example, when mOS0 = 10 and
power is relatively low, more than 99% of simulations gave a lower p-value for the mWLR test than
for standard LR.
The previous example with p = 1 is the most challenging scenario, but it is where mWLR most
clearly dominates the LR test. With the correct treatment switching assumption (i.e., p′ = p),
mWLR outperforms the standard LR test for all values of p. However, as presented in Figure 7,
the benefit is practically neglectable if the degree of treatment switching is low. In fact, we do not
think that the mWLR test is worthwhile if p is known to be small, say p ≤ 0.4. On the other
hand, the efficiency gain of 5% when p = 0.5 is not neglectable since a 5% decrease in sample
size may translate into high cost savings. An even clearer indication for using mWLR is when the
investigator team fears that p ≥ 0.75. For example, when a trial is designed, the “best guess” of the
probability of treatment switching after disease progression may be p′ = 0.6, where the efficiency
of mWLR with respect standard LR is about 110% if p′ = p. However, the prediction of p′ may
be quite uncertain, ranging from rather low treatment switching, where LR would do well, up to
perhaps p′ = 0.75 (with a potential efficiency of around 120%) or even p′ = 0.9 (with an efficiency
of 148%) if p′ = p. Such situations, where p′ is uncertain when pre-specifying the analysis, will be
further explored in the next subsection.
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Figure 7: Efficiency of the modified weighted log-rank (mWLR) test with respect to the log-rank
(LR) test assuming matching values of p and p′ (i.e., (p = 0, p′ = 0), (p = 0.1, p′ = 0.1), . . . , (p =
1, p′ = 1)) for a fixed value of mOS0 = 10 months.
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5.2 Robustness
As indicated by Figure 7, efficiency is increasing rapidly as p increases, with a value of 187% when
p = 1 and p′ = 1. The downside is that, assuming p′ = 1, mWLR is only better than LR when
p > 0.7 and has an efficiency lower than 100% when treatment switching after disease progression
is p ≤ 0.7, as presented in Figures 8A and 8B. We could argue that mWLR with p′ = 1 is relatively
robust when we are convinced that treatment switching will be very high. However, choosing a
somewhat lower design parameter, p′, will give a more robust test if p is not known to be 1.
By construction of the test, it is not surprising that mWLR is the best test for a certain value of
p if designed with the matching treatment switching parameter (i.e., p′ = p) as presented in Figure
9B, where the dot in each curve represent the value of p′ that maximizes efficiency of mWLR with
respect to LR for a given value of p.
For a practical situation in a scenario with the characteristics presented in Section 4, a large
expected treatment switching, but also a relatively large uncertainty around p′, one solution could
be to assume p′ = 0.7 for the following reasons:
i The test is optimal if p′ = p.
ii It is more efficient than the standard LR if p ≥ 0.7 with efficiency values that go from 115%
p = 0.7 to 160% at p = 1 (see Figure 9A).
iii If p < 0.7, it would still be more efficient than standard LR for values of p ≥ 0.45.
iv If p < 0.45, the loss would still be rather limited, especially for values of p ≥ 0.3 where the
efficiency is above 96%.
v If p = 0, the test has an efficiency of 87%.
Thus, mWLR with p′ = 0.7 shows a balance between being robust to mid-degrees of treatment
switching while having large efficiency for high-degree treatment switching with respect to the
standard LR test.
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Figure 8: Power of the modified weighted log-rank (mWLR) test and the log-rank (LR) test (plot
A) and efficiency of the mWLR test with respect to the LR test (plot B) assuming a fixed value of
mOS0 = 10 months, a fixed value of p
′ = 1, and varying the value of p between 0 and 1.
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As noted, the relative values of the medians are much more important for the results than the
absolute values. The model is time-scale invariant. This means that, if all times, medians, etc., were
multiplied with a factor 2, say, the power would be the same. Follow-up and inclusion time also has
to be expanded for this to hold exactly, but as long as maturity (the fraction of patients followed
to death) does not change much, the impact of these times is rather limited. Of greater interest
is what happens if median time to progression is changed relative to median OS. Supplementary
material contains replications of Figure 9B when mPFS0 is 1 and 4 months, respectively, instead of
2 as in the main model (see Figures S1 and S2 respectively). When mPFS0 = 1, patients progress
faster with respect to mPFS0 = 2, which translates into higher values of q (i.e., a larger proportion of
patients that actually switch after disease progression before dying) and therefore a higher efficiency
of mWLR with respect to LR compared to the one observed with mPFS0 = 2. In contrast, when
mPFS0 = 4, patients progress slower which translates into lower values of q and therefore a lower
efficiency of mWLR with respect to LR compared to the one observed with mPFS0 = 2. However,
these differences are in line with how the test is constructed and we can say the conclusions obtained
using mPFS0 equal to 1 and 4 are qualitatively the same to the conclusions obtained with m
PFS
0 = 2.
5.3 Comparison with other methods
In this section we provide a comparison with two methods that have been receiving quite a lot of
attention in the last years given their good performance under non-proportional hazard with respect
to the standard LR test: the Max Combo test [21, 28] and the test based on the restricted mean
survival time [42].
It is important to mention that the test based on the restricted mean survival time is highly
depending on the truncation time. Hence, in order to have an objective and fair comparison between
these tests, the truncation time for the test based on the restricted mean survival time is linked to
the data and is pre-specified as the minimum of the maximum observed event or censored time of
each arm (i.e., minimax observed time).
With respect to the Max Combo test and following Roychoudhury et al. [41], we implement it
considering the maximum of four correlated Fleming-Harrington class of weights: (ρ = 0, γ = 0),
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Figure 9: Efficiency between the modified weighted log-rank (mWLR) test and the log-rank (LR)
test assuming a fixed value of mOS0 = 10 months and varying both p and p
′ between 0 and 1. Values
above 100% favor mWLR and values below 100% favor LR.
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(ρ = 1, γ = 0), (ρ = 0, γ = 1) and (ρ = 1, γ = 1).
This comparison is made using the same set-up as in Section 5.1 which is realistic and similar
to the RECORD-1 trial. The efficiency of mWLR with respect to the test based on the restricted
mean survival time (Figure 10A), shows that when the recommended value p′ = 0.7 is used, in a
scenario with these characteristics, mWLR is more efficient that the test based on the restricted
mean survival time for p ≥ 0.45, reaching an efficiency of 137% when p = 1, and 112% when
p = 0.7 where the test is optimal. Moreover, the efficiency loss for p < 0.45 is rather limited with
an efficiency of 90% even when p = 0.
The efficiency of mWLR with respect to the Max Combo test (Figure 10B), shows that in a
scenario with these characteristics, using the recommended value p′ = 0.7, mWLR is as good as,
or more efficient than the Max Combo test for all values of p, reaching an efficiency of 200% when
p = 1. For values of p ≤ 0.3 however, the performance between mWLR and Max Combo is similar
with efficient values below 105%.
Overall, these results are in line with the results obtained in Section 5.2 where the test is fairly
robust for p′ = 0.7 also in comparison with other testing alternatives particularly suitable for
scenarios where the proportional hazards assumption does not hold.
6 Discussion
In this article we propose a new class of weighted log-rank (WLR) tests to be used when treatment
efficacy is decreasing over time. The motivating application is when a substantial amount of patients
in the control group switches during the clinical trial to a more effective treatment. This is, for
ethical reasons, often occurring in phase III oncology clinical trials. However, the proposed test or
another test based on the same idea may be applicable in other situations when there is a similar
pattern of decreasing efficacy over time. One example outside of the treatment switching application
is when the experimental treatment affects only one of several risk components. More precisely, if
a trial is including patients with a recent stroke, a drug that is effective in preventing (new) strokes
may show large benefit on all-cause mortality in an initial phase. However, the hazard ratio will
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Figure 10: Efficiency between the modified weighted log-rank test (mWLR) with respect to the
test based on the restricted mean survival time (plot A), and efficiency between mWLR test with
respect to the Max Combo test (plot B) assuming a fixed value of mOS0 = 10 months varying p
between 0 and 1, and p′ between 0.5 and 1. Values of efficiency over 100% favor the mWLR test
and values below 100% favor the test based on the restricted mean survival time or the Max Combo
test.
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gradually increase over time when the relative risk of stroke-related deaths starts to decrease and
other causes of mortality start to be present in a large part of the total number of deaths.
According to the FDA [16], endpoints for later phase efficacy studies evaluate whether a drug
provides a clinical benefit such as prolongation of survival or an improvement in symptoms. In
oncology late phase clinical trials, overall survival (OS) is usually the preferred endpoint for final
approval since it does not rely on any assumption, although progression-free-survival (PFS) is often
accepted for conditional approval, awaiting direct evidence of a survival benefit. The FDA [15]
also acknowledges that in most trials, some patients may not receive the treatment assigned by
randomization because of poor response, improvement or worsening of disease, or high toxicity
among other reasons. In general, informative dropout may be of concern even if it occurs before
the initiation of treatment as it can cause a distortion of the results. However, despite the potential
treatment effect dilution that an intent-to-treat (ITT) analysis may cause, this type of analysis is
the gold standard in confirmatory trials. The reason is that it ensures that the comparability of
populations created by randomization is maintained and reduces the risk that bias will be introduced
during the trial or during the analysis. Treatment switching obviously may distort what would have
happened if patients would have been treated only with the drugs from the treatment arms in which
they were randomized. However, even if it is possible to model what the relative efficacy would
have been without treatment switching, such a model cannot be based solely on randomization
since unknown factors will influence which patients from the control arm switch treatment.
In this article we are motivated by the RECORD-1 trial, a phase III clinical trial that compares
placebo with everolimus in patients with metastatic renal-cell carcinoma where almost 80% of the
patients switched from the placebo arm to receive everolimus after disease progression. Figure
1B shows that placebo patients who switched treatment had much longer average survival than
those who did not switch treatment as presented in Figure 1C. However, this comparison is not
randomization-based. One of the key questions is why some patients choose to switch, or not
to switch, treatment? One could for example imagine that patients from the placebo arm with
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particularly poor prognosis could receive palliative care instead of a new treatment with potential
side effects. Techniques used to analyse observational data could be useful for example to determine
the magnitude of an effect in patients actively taking a drug. However, a statistically significant
ITT comparison between two randomized groups would provide more robust evidence of treatment
efficacy, although sometimes the ITT analysis of OS is not feasible given ethical constraints. The
methodology proposed in this article aims to increase the power in an ITT analysis under a high
proportion of patients that switch treatment after disease progression.
The most common test used for confirmatory time-to-event clinical trials is the unweighted
log-rank test (LR). However, given that nonparametric tests are relatively infrequent for primary
analyses in other clinical trials, one may ask why LR is so popular for survival trials. One answer
is that common parametric test alternatives often are relatively in-efficient [8]. If the hazard ratio
is constant over time, the unweighted LR test is the most powerful test. Proportional hazards
is a decent approximation in some cases, but there are many examples where this assumption
does not hold. One area in which this assumption is clearly not met is immuno-therapy (see e.g.,
Rahman [37]). However, from our point of view, it is a mistake to think that the LR should have
a general precedence because it is labelled as ”unweighted”. One may view the Wilcoxon test [31]
as a weighted version of the LR test, but one could equally well view LR as a weighted version of
Wilcoxon. The fact is that LR is equivalent to attributing a certain strictly decreasing ”score” to
each observation, depending on its rank order (see Leton and Zuloaga [29]). We argue that different
scores (or LR weights) should be used when they can be pre-specified to give considerably higher
power while strongly controlling the type-I error.
The Fleming-Harrington class of weights can be used with strictly decreasing weights under the
presence of treatment switching. However, if weights are not strictly decreasing then type-I error is
not controlled as showed by Magirr and Burman [30]. This also holds for the Max Combo test, which
is an omnibus test with four different Fleming-Harrington test components. A difference between
our proposal and the Fleming-Harrington class of weights is that our weights are functions of time,
instead of functions of the estimated pooled survival function. A benefit is that it is more natural
to model the effect under treatment switching in the time scale. Also, as seen in the simulation
results presented in this article, our test mostly outperforms the Max Combo test.
Hypothesis tests should be complemented with clinically relevant estimates. The Kaplan-Meier
curves, together with censoring patterns, give essentially all information, although more condensed
measures are also valuable. Median survival and survival at, for instance, 2 years are clinically
meaningful. Cure rate (if applicable) and otherwise (restricted) mean survival may have even
greater bearing. These parametric estimates are useful complements to a statistical significance,
but they are often too variable to themselves correspond to efficient hypothesis tests. LR tests,
weighted or unweighted, can give estimates of an average hazard ratio or a parametric hazard
ratio time function. This can be done by simply multiplying the number of patients at risk in the
experimental arm with the tentative hazard ratio when calculating the LR statistic. The hazard
ratio that makes the test statistic equal zero leads to the hazard ratio estimate. The problem with
this is that, for example, an estimated average hazard ratio is difficult to interpret when hazards
are meaningfully non-proportional.
In this article, we have promoted the use of pre-specified LR tests with non-increasing weights
that correspond to the predicted hazard ratio function over time. We have developed one class of
weights using prior information regarding median times to progression and to death, depending on
actual treatment, as well as about the expected probability of treatment switching. For a concrete
clinical trial, it may be possible to develop other models for the hazard ratio function, better
tailored to existing pre-clinical and early-phase clinical data, other indications, competitor data,
clinical judgment etc. (see Burman and Wiklund [7]).
We also tested the robustness of our proposal under hazard ratio model misspecification. In other
words, we have assumed an expected probability of treatment switching and tested its performance
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when the true proportion of patients after disease progression that switch does not match the
expected probability of treatment switching. In this evaluation, we found that the performance is
clearly dependent on the accuracy of the expected probability of treatment switching. When the
degree of treatment switching, p is uncertain, we recommend designing the modified test based on
a slightly lower value of p than the best guess estimate, to give higher robustness. The comparisons
also evaluate a median OS misspecification in the control arm. In this case, the model is not very
sensitive to the median OS value used to defined the hazard ratio function and there are not big
differences in terms of performance.
Some possible extensions of the current work could consider situations where the probability
of treatment switching depends on calendar time (when the experimental drug gets more avail-
able), OS hazards increasing after progression and/or depending on time of progression, and other
distributions than exponential.
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